EUVIMEDEUVIMED entdecken
Open Access

KRAS Mutations in Cholangiocarcinoma: Prevalence, Prognostic Value, and KRAS G12/G13 Detection in Cell-Free DNA

Pitchasak Thongyoo, Jarin Chindaprasirt, Chaiwat Aphivatanasiri, Piyapharom Intarawichian, Waritta Kunprom, Sarinya Kongpetch, Anchalee Techasen, Watcharin Loilome, Nisana Namwat, Attapol Titapun, Apinya Jusakul

Cancer Genomics - Proteomics · 2025

DOI: 10.21873/cgp.20492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Genomics - Proteomics, 2025. Verfasst von Pitchasak Thongyoo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thai…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Proto-Oncogene Proteins p21(ras), Mutation, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Cholangiocarcinoma (CCA) is an aggressive hepatobiliary malignancy characterized by genomic heterogeneity. KRAS mutations play a significant role in influencing patient prognosis and guiding therapeutic decision-making. This study aimed to determine the prevalence and prognostic significance of KRAS mutations in CCA, asses the detection of KRAS G12/G13 mutations in plasma cell-free DNA (cfDNA), and evaluate the prognostic value of KRAS G12/G13 mutant allele frequency (MAF) in cfDNA in relation to clinicopathological data and patient survival. MATERIALS AND METHODS: A retrospective analysis of 937 CCA patients was performed using data from cBioPortal to examine KRAS mutation profiles and their association with survival. Plasma from 101 CCA patients was analyzed for KRAS G12/G13 mutations in the cfDNA using droplet digital PCR, and the results were compared with tissue-based sequencing from 78 matched samples. RESULTS: KRAS driver mutations were found in 15.6% of patients, with common variants being G12D (37.0%), G12V (24.0%) and Q61H (8.2%). Patients harboring KRAS mutations exhibited decreased overall and recurrence-free survival. KRAS G12/G13 mutations were detected in 14.9% of cfDNA samples, showing moderate concordance with tissue sequencing, and achieving 80% sensitivity and 93% specificity. Elevated KRAS G12/G13 MAF in cfDNA, combined with high CA19-9 levels, correlated with poorer survival outcomes. CONCLUSION: The presence of KRAS mutations was associated with poor survival in CCA, underscoring the importance of KRAS mutations as prognostic markers. The detection of KRAS mutations in cfDNA demonstrated potential as a promising non-invasive alternative for mutation detection and, when combined with CA19-9 levels, may improve prognostic efficacy in CCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaProto-Oncogene Proteins p21(ras)MutationCell-Free Nucleic AcidsBile Duct NeoplasmsHumansMaleFemalePrognosisMiddle AgedRetrospective StudiesAgedBiomarkers, TumorPrevalenceAdult

Stichwörter der Autor:innen

Cell-free DNAKRAScholangio-carcinomacirculating tumor DNAdigital droplet PCRliquid biopsy

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanCell-Free Nucleic AcidsBiomarkers, Tumor

Autor:innen und Institutionen

  • Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.
  • Medical Oncology Program, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Thailand.
  • Department of Systems Biosciences and Computational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Zitieren

APA

Thongyoo, P., Chindaprasirt, J., Aphivatanasiri, C., Intarawichian, P., Kunprom, W., Kongpetch, S., Techasen, A., Loilome, W., Namwat, N., Titapun, A., & Jusakul, A. (2025). KRAS Mutations in Cholangiocarcinoma: Prevalence, Prognostic Value, and KRAS G12/G13 Detection in Cell-Free DNA. Cancer Genomics - Proteomics. https://doi.org/10.21873/cgp.20492

Vancouver

Thongyoo P, Chindaprasirt J, Aphivatanasiri C, Intarawichian P, Kunprom W, Kongpetch S, et al. KRAS Mutations in Cholangiocarcinoma: Prevalence, Prognostic Value, and KRAS G12/G13 Detection in Cell-Free DNA. Cancer Genomics - Proteomics. 2025. doi:10.21873/cgp.20492

BibTeX
@article{Thongyoo2025,
  author = {Thongyoo, Pitchasak and Chindaprasirt, Jarin and Aphivatanasiri, Chaiwat and Intarawichian, Piyapharom and Kunprom, Waritta and Kongpetch, Sarinya and Techasen, Anchalee and Loilome, Watcharin and Namwat, Nisana and Titapun, Attapol and Jusakul, Apinya},
  title = {KRAS Mutations in Cholangiocarcinoma: Prevalence, Prognostic Value, and KRAS G12/G13 Detection in Cell-Free DNA},
  journal = {Cancer Genomics - Proteomics},
  year = {2025},
  doi = {10.21873/cgp.20492}
}
Kostenlos starten →